The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Alliance A071401: Phase II trial of FAK inhibition in meningiomas with somatic NF2 mutations.
 
Priscilla Kaliopi Brastianos
Honoraria - Angiochem; Genentech; Merck
Consulting or Advisory Role - Angiochem; ElevateBio; Genentech/Roche; Lilly; Tesaro
Research Funding - Bristol-Myers Squibb (Inst); Lilly; Merck; Pfizer
 
Erin Twohy
No Relationships to Disclose
 
Elizabeth Robins Gerstner
Consulting or Advisory Role - Array BioPharma (I); Blue Earth Diagnostics; MyoKardia (I)
 
Timothy J. Kaufmann
No Relationships to Disclose
 
A. John Iafrate
Stock and Other Ownership Interests - Archer
Consulting or Advisory Role - Chugai Pharma; Debiopharm Group; Repare Therapeutics; Repare Therapeutics; Roche
Research Funding - Sanofi; Sanofi
Patents, Royalties, Other Intellectual Property - ArcherDx exclusive license to AMP technology
 
Suriya A. Jeyapalan
No Relationships to Disclose
 
David Eric Piccioni
Consulting or Advisory Role - Tocagen
 
Andrew B. Lassman
Honoraria - Abbott Molecular; WebMD
Consulting or Advisory Role - Abbvie; Agios; Bayer; BioClinica; FORMA Therapeutics; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; QED Therapeutics; SapVax
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Agios (Inst); Amgen (Inst); Bayer (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Keryx (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Orbus Therapeutics (Inst); Pfizer (Inst); QED Therapeutics (Inst); VBI Vaccines (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier
Travel, Accommodations, Expenses - Oncoceutics
 
Camilo E. Fadul
No Relationships to Disclose
 
David Schiff
Consulting or Advisory Role - Monteris Medical; Orbus Therapeutics
Research Funding - Bayer (Inst)
 
Jennie Webster Taylor
Research Funding - Abbvie; Agios; Bristol-Myers Squibb
 
Sajeel A. Chowdhary
No Relationships to Disclose
 
Thomas Joseph Kaley
No Relationships to Disclose
 
Tara Morrison
Employment - Lehigh Valley Health Network; University of Pennsylvania (I)
Travel, Accommodations, Expenses - Lehigh Valley Health Network
 
Priya Kumthekar
Leadership - Vivacitas Oncology
Stock and Other Ownership Interests - Vivacitas Oncology
Consulting or Advisory Role - Abbvie; Orbus Therapeutics
Research Funding - Abbvie; DNAtrix; Genentech/Roche; Novocure; Orbus Therapeutics
Patents, Royalties, Other Intellectual Property - Utility patent for ANG 1005. No financial gain, no royalties.
 
Susan Geyer
No Relationships to Disclose
 
Daniel P. Cahill
Honoraria - Merck
Consulting or Advisory Role - Lilly
Travel, Accommodations, Expenses - Merck
 
Sandro Santagata
Consulting or Advisory Role - RareCyte
Patents, Royalties, Other Intellectual Property - "Targeted Manipulation of the Proteasome Subunit Expression Levels as a Method for Curing Cancer” Application pending; “Combination Treatments of Hsp90 Inhibitors for Enhancing Tumor Immunogenicity and Methods of Use Thereof” Application pending; US20150241436A1 Hsf1 and hsf1 cancer signature set genes and uses relating thereto Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor dia; US20170037480A1 Hsf1 in tumor stroma Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products in tumor stroma. In some aspects, the invention provides methods of tumor prognosis, treatment-specific pre; US20170037480A1 Hsf1 in tumor stroma Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products in tumor stroma. In some aspects, the invention provides methods of tumor prognosis, treatment-specific pre; US20180306796A1 Methods and compositions relating to proteasome inhibitor resistance Abstract In some aspects, the disclosure provides methods of modulating the level of proteasome inhibitor resistance of a cell, the methods comprising manipulating th; US9696313B2 HSF1 as a marker in tumor prognosis and treatment Abstract In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, trea
 
Frederick G. Barker
No Relationships to Disclose
 
Evanthia Galanis
Consulting or Advisory Role - Abbvie (Inst); Celgene; Genentech/Roche (Inst); Karyopharm Therapeutics (Inst); KIYATEC; Oncorus
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); TRACON Pharma (Inst)